NextCure (NASDAQ:NXTC – Get Free Report)‘s stock had its “buy” rating reaffirmed by stock analysts at HC Wainwright in a report released on Friday, Benzinga reports. They currently have a $8.00 price target on the stock. HC Wainwright’s target price would suggest a potential upside of 422.88% from the company’s previous close. Separately, Needham & […]
Marquette Asset Management LLC acquired a new stake in shares of NextCure, Inc. (NASDAQ:NXTC – Free Report) during the 4th quarter, Holdings Channel.com reports. The firm acquired 58,259 shares of the company’s stock, valued at approximately $66,000. Separately, Acuitas Investments LLC raised its holdings in NextCure by 30.0% during the 4th quarter. Acuitas Investments LLC […]
NextCure, Inc. (NASDAQ:NXTC – Get Free Report) was the target of a significant growth in short interest in March. As of March 15th, there was short interest totalling 839,700 shares, a growth of 579.9% from the February 29th total of 123,500 shares. Based on an average trading volume of 229,500 shares, the short-interest ratio is […]
NextCure, Inc. (NASDAQ:NXTC – Get Free Report) was the target of a significant decrease in short interest during the month of January. As of January 31st, there was short interest totalling 108,900 shares, a decrease of 11.8% from the January 15th total of 123,400 shares. Based on an average daily volume of 91,000 shares, the […]
BELTSVILLE, Md., Dec. 21, 2023 (GLOBE NEWSWIRE) NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and.